The year 2024 marked a pivotal moment for the pharmaceutical industry as stakeholders prepared for the Drug Supply Chain Security Act (DSCSA) interoperability deadline on November 27. The legislation, designed to strengthen pharmaceutical products’ security and traceability, posed significant opportunities and challenges for manufacturers, wholesalers, and other supply chain participants. Below is a summary of key developments that shaped the year.
Readiness Leading up to the November 27, 2024 Deadline
In the months leading up to the November 27 deadline, industry stakeholders focused on achieving full compliance. While many organizations demonstrated significant progress, readiness levels varied, highlighting disparities in resource allocation and system maturity, all of which were brought forth during the PDG/FDA joint public meeting in June and again during the HDA Traceability Seminar in August. The FDA was clear that they heard and understood the industry’s concerns and their main concern was to prevent any supply chain disruptions for patients.
FDA’s Exemption Announcement
On October 9, 2024, the FDA issued an exemption to mitigate widespread industry concerns about the ability to meet compliance requirements on time. The exemption provided temporary relief, allowing supply chain participants additional time to address lingering gaps. The duration of the exemption depends on the type of trading partner:
- Manufacturers and Repackagers: May 27, 2025
- Wholesale Distributors: August 27, 2025
- Dispensers with 26 or more full-time employees: November 27, 2025
The exemption emphasized that it applies to “eligible trading partners,” which are “trading partners who have successfully completed or made documented efforts to complete data connections with their immediate trading partners but still face challenges exchanging data.” The industry discussed what these documented efforts might look like and how trading partners can confirm their eligibility under these requirements.
Trading partners who utilize these exemptions do not need to notify the FDA, but many choose to inform their trading partners that they plan on taking advantage of the exemption. This exemption was widely seen to supersede any previous WEEs submitted to the FDA before this announcement.
While this announcement was welcomed by many, it also underscored the complexity of achieving seamless interoperability across the pharmaceutical ecosystem. The exemption also raised questions about the industry’s ability to maintain momentum and avoid complacency in addressing remaining challenges.
Improvement of Wholesaler Scorecards
Wholesaler scorecards emerged as a critical tool for assessing supply chain performance and compliance. While the scorecards showed marked improvements like data accuracy and traceability, they also highlighted persistent gaps in the industry’s ability to investigate and resolve exceptions. These gaps underscore the need for ongoing collaboration and investment in advanced technologies to support seamless exception management.
Looking Ahead to 2025: Deadlines, Requirements, and Opportunities
Now, in 2025, the pharmaceutical industry is focused on meeting upcoming deadlines and applying the valuable lessons learned from 2024. Here’s what to expect moving forward:
New Deadlines for Manufacturers and Wholesalers
With the FDA’s exemption effectively resetting the compliance timeline, manufacturers and wholesalers face new deadlines in 2025, as stated above. These deadlines are expected to bring renewed urgency to system enhancements, data integration efforts, and compliance verification processes. Meeting these requirements will necessitate a collaborative approach, with all stakeholders working together to achieve DSCSA objectives.
Some wholesalers have established their own deadlines ahead of the new FDA deadline. McKesson has not rolled back its deadline, which went into effect in August 2024. Cencora has stated that it will begin quarantining products that arrive at its distribution centers without data by May 1, 2025. As is often the case with DSCSA, trading partners are beholden to their customers regarding when they must adhere to these requirements.
Expected Improvements in 2025
The lessons of 2024 will drive significant improvements in 2025, particularly in the following areas:
- Enhanced Data Accuracy: Advanced systems and better integration are expected to reduce discrepancies and improve the overall reliability of serialized data.
- Streamlined Exception Management: Industry stakeholders are likely to adopt new tools and processes to address exceptions more efficiently, minimizing disruptions to the supply chain.
- Stronger Collaboration: Increased collaboration among manufacturers, wholesalers, and other stakeholders will support a more unified approach to achieving DSCSA compliance.
The path to DSCSA compliance remains a work in progress. While 2024 revealed critical gaps and challenges, the exemption announcement provided an opportunity for a sigh of relief throughout the industry before continuing forward with the commitment to improving supply chain security. Now, in 2025, stakeholders must continue building on these efforts, leveraging new opportunities to enhance data accuracy, streamline processes, and foster greater collaboration. By doing so, the pharmaceutical industry can finally achieve the DSCSA’s final vision of a safer, more secure supply chain for all.